[{"orgOrder":0,"company":"Eurobio Scientific","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"AGN-231868","moa":"Chemokine receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Eurobio Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Eurobio Scientific \/ Allergan Aesthetics","highestDevelopmentStatusID":"8","companyTruncated":"Eurobio Scientific \/ Allergan Aesthetics"}]

Find Clinical Drug Pipeline Developments & Deals by Eurobio Scientific

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : During the clinical development of AGN-231868, Eurobio Scientific remains eligible to other milestone payments linked to successful transitions to further clinical stages.

                          Product Name : AGN-231868

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 10, 2021

                          Lead Product(s) : AGN-231868

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Allergan Aesthetics

                          Deal Size : $5.0 million

                          Deal Type : Collaboration

                          blank